Heron Therapeutics

HRTX

Market cap $89.1M

HRTX Hedge Fund Activity: Q1 2026 in Review

167 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q1 2026, worth a combined $126M — down 39% from $207M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new HRTX positions and 29 closed out — a net gain of 2 holders — while 52 added to existing stakes and 43 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $11.4M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $14.5M sold.

• 167 institutional investors held Heron Therapeutics (HRTX) as of Q1 2026, down from 170 in Q4 2025.
• Funds reported $126M of Heron Therapeutics stock for Q1 2026, down 39% quarter-over-quarter.
• 31 funds opened new Heron Therapeutics positions in Q1 2026 and 29 closed out, a net change of +2 holders.
• The largest Heron Therapeutics buyer in Q1 2026 was OrbiMed, an estimated $11.4M added.
• The largest Heron Therapeutics seller in Q1 2026 was Adage Capital Partners, an estimated $14.5M sold.

Based on aggregated 13F filings for Q1 2026.